Venturelab
close

First neurostimulator to treat erectile dysfunction

Comphya SA

Swiss Startup - Comphya Profile Main Image
Incorporated
02.06.2017
Headquarters
Ecublens
Support

We are developing an active implantable medical device, named CaverSTIM, to restore the erectile function of post-prostatectomy patients or others non-responsive to oral drugs (e.g. Viagra or Cialis). To achieve erection, these patients resort to intrapenial injections of vasodilators or penile implants, which are quite problematic and outdated, but the only option for a large population (approx. 1B existing market). CaverSTIM offers a far better therapeutic modality for an under-addressed market.

News

28.01.2026

New studies validate Aesyra and Comphya devices (startupticker.ch)

31.01.2023

Comphya raises funds for clinical trials (startupticker.ch)

06.12.2021

Tech tour presents 12 winners from Switzerland (startupticker.ch)

14.10.2021

Alpine Techstars to attract investors (startupticker.ch)

02.12.2020

Comphya raises additional USD 1.3 million (startupticker.ch)

18.02.2020

10 Swiss Medtech Startups to Watch in 2020 (venturelab.swiss)

Show all

Milestones news

10.08.2023

Start of 2 Pilot Clinical Trials

Show all
Swiss Startup - Comphya Product Image Swiss Startup - Comphya Team Image Swiss Startup - Comphya Additional Image